Rafael Scheliga Segovia

Rafael Scheliga Segovia

Auto-generated profile, based on publicly available information

Rafael Scheliga Segovia

Universidade de São Paulo, Brasil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MYMegumi Nishitani Yukuyama
Megumi Nishitani Yukuyama
LGLara Mendes Ferreira Guimaraes
Lara Mendes Ferreira Guimaraes
RSRafael Scheliga Segovia
Rafael Scheliga Segovia
CLClaudiana Lameu
Claudiana Lameu
GAGabriel Lima Barros de Araujo
Gabriel Lima Barros de Araujo
NBNádia Araci Bou-Chacra
Nádia Araci Bou-Chacra

1 January 2024 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
MMMarluce Mantovani
Marluce Mantovani
NDNilsa Regina Damaceno-Rodrigues
Nilsa Regina Damaceno-Rodrigues
GRG.T.S. Ronatty
G.T.S. Ronatty
RSR.S. Segovia
R.S. Segovia
CPCarlos Andrés Pantanali
Carlos Andrés Pantanali
MSMari Sogayar
Mari Sogayar
Pancreatic bioengineering is a potential therapeutic alternative for type 1 diabetes (T1D) in which the pancreas is decellularized, generating an acellular extracellular matrix (ECM) scaffold, which may be reconstituted by recellularization with several cell types to generate a bioartificial pancreas. No consensus for an ideal pancreatic decellularization protocol exists. Therefore, we aimed to determine the best-suited detergent by comparing sodium dodecyl sulfate (SDS), sodium deoxycholate (SDC), and Triton X-100 at different concentrations. Murine (n=12) and human pancreatic tissue from adult brain-dead donors (n=06) was harvested in accordance with Institutional Ethical Committee of the University of São Paulo Medical School (CEP-FMUSP) and decellularized under different detergent conditions. DNA content, histological analysis, and transmission and scanning electron microscopy were assessed. The most adequate condition for pancreatic decellularization was found to be 4% SDC, displaying: a) effective cell removal; b) maintenance of extracellular matrix architecture; c) proteoglycans, glycosaminoglycans (GAGs), and collagen fibers preservation. This protocol was extrapolated and successfully applied to human pancreas decellularization. The acellular ECM scaffold generated was recelullarized using human pancreatic islets primary clusters. 3D clusters were generated using 0.5×104 cells and then placed on top of acellular pancreatic slices (25 and 50 μm thickness). These clusters tended to connect to the acellular matrix, with visible cells located in the periphery of the clusters interacting with the ECM network of the bioscaffold slices and continued to produce insulin. This study provided evidence on how to improve and accelerate the pancreas decellularization process, while maintaining its architecture and extracellular structure, aiming at pancreatic bioengineering.